Michael Joannidis
Zaccaria Ricci
Miet Schetz

Feeding the kidneys in AKI: no appetite for a change in practice

Received: 11 May 2015
Accepted: 12 May 2015
Published online: 22 May 2015
© Springer-Verlag Berlin Heidelberg and ESICM 2015

This is an editorial linked to the article with
doi:[10.1007/s00134-015-3827-9](https://doi.org/10.1007/s00134-015-3827-9).

M. Joannidis (✉)
Division of Intensive Care and Emergency Medicine, Department
of Internal Medicine, Medical University of Innsbruck,
Anichstrasse 35, 6020 Innsbruck, Austria
e-mail: michael.joannidis@i-med.ac.at
Tel.: +43-512-504-81404

Z. Ricci
Pediatric Cardiac Intensive Care Unit, Department of Pediatric
Cardiology and Cardiac Surgery, Bambino Gesù Children's
Hospital, IRCCS, Piazza S. Onofrio 4, 00165 Rome, Italy

M. Schetz
Division of Cellular and Molecular Medicine, Clinical Department
and Laboratory of Intensive Care Medicine, Herestraat 49, 3000
Louvain, Belgium

The quest for the “silver bullet” to protect kidney function in critical illness has been largely unsuccessful over recent decades. Most of these “negative” clinical investigations concentrated on selective increases of renal blood flow (RBF) and glomerular filtration rate (GFR) using adenosine agonists, natriuretic peptides, prostaglandins, renal dose dopamine [1], or just recently fenoldopam [2].

Infusion of amino acids (AA) has been demonstrated to improve both RBF and GFR in animal experiments [3] as well as in some pilot trials in humans [4, 5]. In the current

issue of *Intensive Care Medicine*, Doig and colleagues [6] present an original, interesting, and well-designed and executed multicenter phase II randomized controlled trial (RCT) investigating the effect of daily infusion of AA on kidney function in a cohort of 474 critically ill patients. Patients with expected intensive care unit (ICU) stay of more than 2 days were randomly assigned to standard care or daily IV supplementation with up to 100 g AA (adapted to achieve a protein intake of 2 g/kg/day) in addition to standard nutrition. The renal effects of the intervention were limited to a statistically significant increase of eGFR (with a peak difference of 7.7 ml/min/1.73 m²) and urinary output (by an average of 300 ml/day), compensating the increased fluid intake. The primary outcome, i.e., duration of renal dysfunction, defined as the number of days (corrected for time at risk) with a serum creatinine above 168 μmol/L (1.9 mg/dL) was, however, not different between control and treatment groups. The same was true for other clinically significant outcomes such as use of renal replacement therapy (RRT), mortality, length of stay, and days of mechanical ventilation.

Scientifically the study proves an ancient physiological concept in nephrology that intravenous administration of AA results in an increased RBF and GFR. This aspect, also known as “renal functional reserve”, simply represents the capacity of the normal kidney to adapt to an increased protein or amino acid load. The underlying mechanism remains largely speculative but is thought to include changes in glomerular hemodynamics due to more afferent than efferent vasodilation, potentially explained by AA-sodium cotransport resulting in decreased distal sodium delivery with reduced activation of the tubuloglomerular feedback [7]. Hormonal effects mediated by glucagon, insulin-like growth factor-1, or growth hormone have also been implicated [8].

The concept of an increase of GFR with infusion of AA is used to establish renal reserve in candidates for living kidney donation. As such it could also be a useful approach to determine susceptibility to acute kidney injury (AKI). The fact that Doig and colleagues could demonstrate an increased eGFR with AA administration also indicates that critically ill patients are capable of activating their renal reserve [6]. The crucial question, however, remains whether activation of renal reserve in the critically ill confers improved clinical outcome. The negative effect on the primary outcome (i.e., duration of renal dysfunction) would suggest that this is not the case. Although one would presume that an improvement of RBF should be protective against AKI, studies in sepsis-associated AKI, the most predominant form of AKI in the critically ill, indicate a limited pathophysiological role for RBF. Indeed, animal models of sepsis show a reduced GFR with enhanced rather than diminished RBF [9]. This lead some authors to hypothesize that a reduced GFR may be even protective for the kidney by reducing oxygen demand and filtration of tubular toxins [10–12]. In addition, a recent animal model of sepsis showed an increased renal vascular resistance and decreased RBF and GFR after an AA infusion [13]. However, the pathophysiology of AKI may be profoundly different in sepsis as compared to other causes like cardiac surgery. Unfortunately, the authors do not provide a discrimination of the effects of AA infusion on various aetiologies of renal dysfunction. Finally, in chronic kidney disease induction of hyperfiltration by protein load has turned out rather detrimental resulting in a more rapid progression of CKD [14].

Besides the questionable value of increasing GFR in critically ill patients, the improvement of eGFR achieved by AA infusion was moderate (amounting to a peak difference of 7.7 ml/min/1.73 m² on day 4) and presumably too small to have a clinical impact. Measured with a cystatin-based equation, the eGFR difference was even smaller. This limitation is further substantiated by the fact that neither the duration of impaired renal function nor the requirement for RRT could be influenced by AA infusion. RRT even tended to be instituted more frequently with AA infusion, possibly triggered by higher blood urea nitrogen (BUN) values resulting from increased AA metabolism. At initiation of RRT other parameters of kidney function (potassium, urine output, pH, serum creatinine) were not worse or even better in the treatment

arm, suggesting that the BUN levels may indeed have driven the decision to start RRT. In addition, after controlling for baseline differences, the trend towards increased need for RRT disappeared.

A major shortcoming of this paper is the definition of renal dysfunction. The authors missed the chance to apply more up-to-date criteria for the definition of AKI (e.g., KDIGO) [15] and, thus, it is conceivable that effects on lower stages of AKI remained undetected as a result of the definition used in the present study applying a fixed cut-off of serum creatinine to define “renal dysfunction”. Using a modern AKI definition based on changes in serum creatinine in comparison with the level at inclusion might have been a better approach to demonstrate an effect on prevention of AKI.

Besides the renal aspect, this trial is also the first RCT comparing guideline-suggested amounts of proteins with lower doses. Current recommendations suggest a daily protein administration of 1.5 g/kg body weight [16, 17], although some authors support doses up to 2.0–2.5 g/kg [18]. By adding AA infusion to standard nutrition, Doig and colleagues applied protein doses up to 2.0 g/kg/day (averaging 1.8 g/kg/day) as compared to 0.8 g/kg/day in the control group. Furthermore, energy provision, which was around 1100 kcal/day in the control group, increased to roughly 1300 kcal/day with AA infusion. Despite the increased caloric and protein intake none of the parameters expected to be influenced by a successful nutritional intervention could be improved. Length of stay, duration of mechanical ventilation, rate of infection, pressure ulcers, quality of life, and physical function in 90-day survivors did not show any difference between the two groups. The only measured effect was increased ureagenesis, confirming results from the EPaNIC trial [19].

All together the results of this trial show us that activation of renal reserve by additional AA infusion is feasible in critically ill patients. Whether this intervention is also renoprotective is far less clear. Its clinical benefit appears at least questionable and future trials, when deemed appropriate, should use modern, more sensitive definitions of AKI, preferably include renal biomarkers, and focus on specific subsets of critically ill patients reflecting different pathophysiologies of AKI.

Conflicts of interest The authors declare that they have no conflict of interests regarding this publication.

References

- Joannidis M, Druml W, Forni LG, Groeneveld AB, Honore P, Oudemans-van Straaten HM, Ronco C, Schetz MR, Woittiez AJ (2010) Prevention of acute kidney injury and protection of renal function in the intensive care unit. Expert opinion of the Working Group for Nephrology ESICM. *Intensive Care Med* 36:392–411
- Bove T, Zangrillo A, Guarracino F, Alvaro G, Persi B, Maglioni E, Galdieri N, Comis M, Caramelli F, Pasero DC, Pala G, Renzini M, Conte M, Paternoster G, Martinez B, Pinelli F, Frontini M, Zucchetti MC, Pappalardo F, Amantea B, Camata A, Pisano A, Verdecchia C, Dal Checco E, Cariello C, Fatta L, Baldassarri R, Scandroglio AM, Saleh O, Lembo R, Calabro MG, Bellomo R, Landoni G (2014) Effect of fenoldopam on use of renal replacement therapy among patients with acute kidney injury after cardiac surgery: a randomized clinical trial. *JAMA* 312:2244–2253
- Boyce AC, Gibson KJ, Wintour EM, Koukoulas I, Lumbers ER (2005) Effects of 7-day amino acid infusion on renal growth, function, and renin-angiotensin system in fetal sheep. *Am J Physiol Regul Integr Comp Physiol* 289:R1099–R1106
- Rodriguez A, Martin A, Oterino JA, Blanco I, Jimenez M, Perez A, Novoa JM (1999) Renal function in compensated hepatic cirrhosis: effects of an amino acid infusion and relationship with nitric acid. *Dig Dis* 17:235–240
- Singer P (2007) High-dose amino acid infusion preserves diuresis and improves nitrogen balance in non-oliguric acute renal failure. *Wien Klin Wochenschr* 119:218–222
- Doig GSF, Bellomo R, Heighes PT, Sweetman EA, Chesher D, Pollock C, Davies A, Botha J, Harrigan P, Reade MC (2015) Intravenous amino acid therapy for kidney function in critically ill patients: a randomized controlled trial. *Intensive Care Med*. doi: [10.1007/s00134-015-3827-9](https://doi.org/10.1007/s00134-015-3827-9)
- Woods LL (1995) Intrarenal mechanisms of renal reserve. *Semin Nephrol* 15:386–395
- King AJ, Levey AS (1993) Dietary protein and renal function. *J Am Soc Nephrol* 3:1723–1737
- Langenberg C, Wan L, Egi M, May CN, Bellomo R (2007) Renal blood flow and function during recovery from experimental septic acute kidney injury. *Intensive Care Med* 33:1614–1618
- Chawla LS, Kellum JA, Ronco C (2012) Permissive hypofiltration. *Crit Care* 16:317
- Brezis M, Rosen S (1995) Hypoxia of the renal medulla—its implications for disease. *N Engl J Med* 332:647–655
- Hirsch S, Hirsch J, Bhatt U, Rovin BH (2012) Tolerating increases in the serum creatinine following aggressive treatment of chronic kidney disease, hypertension and proteinuria: pre-renal success. *Am J Nephrol* 36:430–437
- Vassal O, Bonnet JM, Barthelemy A, Allaouchiche B, Goy-Thollot I, Louzier V, Paquet C, Ayoub JY, Dauwalder O, Jacquet-Lagrange M, Junot S (2015) Renal haemodynamic response to amino acids infusion in an experimental porcine model of septic shock. *Acta Anaesthesiol Scand* 59:598–608
- Levey AS, Adler S, Caggiula AW, England BK, Greene T, Hunsicker LG, Kusek JW, Rogers NL, Teschan PE (1996) Effects of dietary protein restriction on the progression of advanced renal disease in the modification of diet in renal disease study. *Am J Kidney Dis* 27:652–663
- Kidney Disease: Improving Global Outcomes (2012) KDIGO clinical practice guideline for acute kidney injury. *Kidney Int Suppl* 2:1–138
- Singer P, Berger MM, Van den Berghe G, Biolo G, Calder P, Forbes A, Griffiths R, Kreyman G, Leverve X, Pichard C, ESPEN (2009) ESPEN guidelines on parenteral nutrition: intensive care. *Clin Nutr* 28:387–400
- Singer P, Hiesmayr M, Biolo G, Felbinger TW, Berger MM, Goeters C, Kondrup J, Wunder C, Pichard C (2014) Pragmatic approach to nutrition in the ICU: expert opinion regarding which calorie protein target. *Clin Nutr* 33:246–251
- Hoffer LJ, Bistrian BR (2012) Appropriate protein provision in critical illness: a systematic and narrative review. *Am J Clin Nutr* 96:591–600
- Gunst J, Vanhorebeek I, Casaer MP, Hermans G, Wouters PJ, Dubois J, Claes K, Schetz M, Van den Berghe G (2013) Impact of early parenteral nutrition on metabolism and kidney injury. *J Am Soc Nephrol* 24:995–1005